Biopharmaceutical News and Research

RSS

Bioniche Life Sciences announces first quarter fiscal 2011 results

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of its 2011 fiscal year (ended September 30, 2010).

10 Nov 2010

Zalicus third quarter total revenue decreases to $1.2 million

"We made solid product development progress this quarter," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "We finalized our development plans for Synavive, and also related to Synavive, we were awarded a Therapeutic Discovery Project grant to help fund Synavive development going forward.

10 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the European Medicines Agency (EMA) granted orphan product designation for SBC-102 (Recombinant Human Lysosomal Acid Lipase), the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency.

10 Nov 2010

NeoPharm, Insys complete merger

NeoPharm, Inc., a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has completed its merger with Insys Therapeutics, Inc., a Phoenix, AZ based pharmaceutical company.

10 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

REF donates $24 million in innovative RA research

The American College of Rheumatology Research and Education Foundation today announced it has raised nearly $28 million, and funded $24 million, in RA research through its Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign - putting the Foundation two million from its initial $30 million goal.

9 Nov 2010

CytRx reports $4.4 million net loss for third quarter 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2010, and provided a business update. The Company also announced the filing of a shelf registration statement with the Securities and Exchange Commission to replace its existing shelf registration, which expires in December 2010.

8 Nov 2010

Progenics third quarter net loss increases to $17.1 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2010.

8 Nov 2010

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

Santarus, Inc. a specialty biopharmaceutical company, today announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate active ulcerative colitis.

8 Nov 2010

BioSpecifics Technologies third quarter net loss increases to $0.5 million

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2010.

8 Nov 2010

GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project program.

8 Nov 2010

Oragenics awarded $733,437 Federal Grant under PPACA Act

Florida-based biopharmaceutical company Oragenics, Inc. announced that it will receive a $733,437 Federal Grant as part of Congress's Patient Protection and Affordable Care Act of 2010.

8 Nov 2010

Agios receives two grants under QTDP program to develop novel cancer metabolism therapies

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced it has received two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.

8 Nov 2010

Omeros third quarter net loss increases to $7.6 million

4 Nov 2010

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

4 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

Biopharmaceutical News and Research

Bioniche Life Sciences announces first quarter fiscal 2011 results

Zalicus third quarter total revenue decreases to $1.2 million

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

NeoPharm, Insys complete merger

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

REF donates $24 million in innovative RA research

CytRx reports $4.4 million net loss for third quarter 2010

Progenics third quarter net loss increases to $17.1 million

Santarus's budesonide MMX drug shows positive result for active ulcerative colitis

BioSpecifics Technologies third quarter net loss increases to $0.5 million

GeoVax receives $244,500 grant under QTDP program for HIV/AIDS vaccine development

Oragenics awarded $733,437 Federal Grant under PPACA Act

Agios receives two grants under QTDP program to develop novel cancer metabolism therapies

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Omeros third quarter net loss increases to $7.6 million

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Event guide: World ADC San Diego eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News